Your Cart Is Empty!
Key Questions Answered in this Update Bulletin:
Will safety concerns related to anti-IL-17 mAbs influence physician adoption of Eli Lilly’s ixekizumab as a treatment for moderate to severe plaque psoriasis?
Following on from regulatory submissions in Europe and the US, do KOLs believe there is a role for AstraZeneca’s/Valeant’s brodalumab as a treatment for moderate to severe plaque psoriasis despite safety concerns?
As a late entrant to the moderate to severe plaque psoriasis treatment landscape, how do KOLs view Cimzia’s chances of success, and what could enable UCB/Dermira to differentiate this product versus other anti-TNF therapies?
If approved, where do KOLs believe Vitae Pharmaceuticals’ VTP-43742 (a novel, orally active RORyt inhibitor) will be used in the moderate to severe plaque psoriasis treatment paradigm?
With several more anti-TNF biosimilars emerging from late-stage development in Europe and the US, what concerns do KOLs have about using these products as treatments for moderate to severe plaque psoriasis, and which programmes are KOLs most excited about?
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
Following are different modes of Licenses.
a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.
b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.
c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.
1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :
a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]
b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]
2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:
a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.